+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia-Pacific Genetic Testing Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4771842
  • Report
  • Region: Asia Pacific
  • 75 pages
  • Mordor Intelligence
1 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd
  • Genomic Health Inc.
  • Illumina Inc.
  • Mapmygenome
  • MORE
Market Overview

The Asia-Pacific Genetic Testing market was valued at USD 1,324.63 million in 2018 and is estimated to be valued at USD 2,481.97 million in 2024, witnessing a CAGR of 11.0%. Certain factors that are driving the market growth include growing demand for personalized medicine and the increased application of genetic testing in oncology.

The FDA has approved several drugs for the treatment of lung cancer. Genetic discoveries over the past decade have transformed the way doctors treat and interpret this disease. Personalized medicine and genetic services play a vital role in wellness, prevention, and selection of cost-saving therapy.

The diagnostic and pharmaceuticals sector in the Asia-Pacific region has gained momentum, owing to speedy adoption and rising technological advancements. This has resulted in the adoption of personalized medicine across the region, including the creation of a pharmacogenomics research network, across the globe.

Scope of the Report

A genetic test is a test performed to identify the presence of a particular gene or set of genes, with a particular sequence of the genome. The genes can be identified either directly through sequencing or indirectly through various methods. Genetic testing practices are rapidly increasing in rare disease diagnostics and for personalized medicines, which is driving the growth of this market.

Key Market Trends

Diagnostic Testing is Expected to Hold its Highest Revenue Share in the Testing Type Segment

By type, diagnostic testing is believed to have the largest market size and is expected to witness a CAGR of 11.18% during the forecast period.

The is due to the detection of diseases and treatment at an early stage to minimize the severity of diseases, leading to a reduced mortality rate. Treatment at an early stage requires diagnostic testing and this is expected to increase the market demand over the forecast period.

In recent years, China has been concentrating increasingly on genetic science, with several trials underway. The country is also quietly at work, building the world’s biggest DNA database. Thus, China is rapidly increasing the appetite for DNA-reading technology, which is helping companies that can help unravel the genetic code grow.

DNA labs in India are ranked as India’s number one Genetic DNA Testing Laboratories. There are 3,000 sample collection centers and tie-ups with 500 hospitals across India. This network performs more than 5,000 tests per day. Hence, all the aforementioned factors are contributing to the growth of the market.

Competitive Landscape

The Asia-Pacific genetic testing market is highly competitive and consists of several major players. In terms of market share, a few major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new ingredients at lower prices. Companies like Abbott Laboratories Inc., Bio-Rad Laboratories Inc., Myriad Genetics Inc., Genomic Health Inc., and Mapmygenome hold the substantial market share in the Asia-Pacific genetic testing market.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd
  • Genomic Health Inc.
  • Illumina Inc.
  • Mapmygenome
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Emphasis on Early Disease Detection and Prevention
4.2.2 Growing Demand for Personalized Medicine
4.2.3 Increasing Application of Genetic Testing in Oncology
4.3 Market Restraints
4.3.1 High Costs of Genetic Testing
4.3.2 Social and Ethical Implications of Genetic Testing
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Carrier Testing
5.1.2 Diagnostic Testing
5.1.3 Newborn Screening
5.1.4 Predictive and Presymptomatic Testing
5.1.5 Prenatal Testing
5.1.6 Other Types
5.2 By Disease
5.2.1 Alzheimer's Disease
5.2.2 Cancer
5.2.3 Cystic Fibrosis
5.2.4 Sickle Cell Anemia
5.2.5 Duchenne Muscular Dystrophy
5.2.6 Thalassemia
5.2.7 Huntington's Disease
5.2.8 Special Diseases
5.2.9 Other Diseases
5.3 By Technology
5.3.1 Cytogenetic Testing
5.3.2 Biochemical Testing
5.3.3 Molecular Testing
5.4 Geography
5.4.1 Asia-Pacific
5.4.1.1 China
5.4.1.2 Japan
5.4.1.3 India
5.4.1.4 Australia
5.4.1.5 South Korea
5.4.1.6 Rest of Asia-Pacific

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Bio-Rad Laboratories Inc.
6.1.3 Myriad Genetics Inc.
6.1.4 Genomic Health Inc.
6.1.5 Mapmygenome
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Thermo Fisher Scientific Inc.
6.1.8 Qiagen NV
6.1.9 Danaher Corporation (Cepheid)
6.1.10 Illumina Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Myriad Genetics Inc.
  • Genomic Health Inc.
  • Mapmygenome
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Qiagen NV
  • Danaher Corporation (Cepheid)
  • Illumina Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4771842
Adroll
adroll